{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:50:01Z","timestamp":1793875801687,"version":"4.7.0"},"reference-count":199,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jhep.2023.01.024","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T12:06:42Z","timestamp":1675426002000},"page":"1048-1062","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":226,"title":["An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease"],"prefix":"10.1016","volume":"78","author":[{"given":"Eunyoung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannelie","family":"Korf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vidal-Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2023.01.024_bib1","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1749-6632.2010.05875.x","article-title":"Adipokines as novel biomarkers and regulators of the metabolic syndrome","volume":"1212","author":"Deng","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jhep.2023.01.024_bib2","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1371\/journal.pbio.0060237","article-title":"It's not how fat you are, it's what you do with it that counts","volume":"6","author":"Virtue","year":"2008","journal-title":"Plos Biol"},{"key":"10.1016\/j.jhep.2023.01.024_bib3","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1172\/JCI28898","article-title":"TLR4 links innate immunity and fatty acid-induced insulin resistance","volume":"116","author":"Shi","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.01.024_bib4","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2023.01.024_bib5","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2023.01.024_bib6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.01.024_bib7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A\u00a0new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.024_bib8","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1053\/j.gastro.2008.01.075","article-title":"Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects","volume":"134","author":"Korenblat","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.01.024_bib9","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.01.024_bib10","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/j.gastro.2007.11.038","article-title":"Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease","volume":"134","author":"Fabbrini","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.01.024_bib11","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/hep.31822","article-title":"Increased adipose tissue fibrogenesis, not impaired expandability, is associated with nonalcoholic fatty liver disease","volume":"74","author":"Beals","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.024_bib12","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2023.01.024_bib13","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/hep.31417","article-title":"Microbiomics, metabolomics, predicted metagenomics, and hepatic steatosis in a population-based study of 1,355 adults","volume":"73","author":"Alferink","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.024_bib14","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1172\/JCI129186","article-title":"Metabolically healthy obesity: facts and fantasies","volume":"129","author":"Smith","year":"2019","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.01.024_bib15","doi-asserted-by":"crossref","first-page":"E930","DOI":"10.1152\/ajpendo.00522.2004","article-title":"Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue","volume":"288","author":"Rasouli","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jhep.2023.01.024_bib16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.cmet.2008.04.004","article-title":"Beneficial effects of subcutaneous fat transplantation on metabolism","volume":"7","author":"Tran","year":"2008","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2023.01.024_bib17","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.cmet.2017.04.015","article-title":"Metabolic flexibility in health and disease","volume":"25","author":"Goodpaster","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2023.01.024_bib18","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.2337\/diabetes.49.12.2102","article-title":"Impaired oxidation of plasma-derived fatty acids in type 2 diabetic subjects during moderate-intensity exercise","volume":"49","author":"Blaak","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.jhep.2023.01.024_bib19","first-page":"E1130","article-title":"Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss","volume":"277","author":"Kelley","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jhep.2023.01.024_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154142","article-title":"Metabolic flexibility is impaired in women who are pregnant and overweight\/obese and related to insulin resistance and inflammation","volume":"104","author":"Tinius","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.jhep.2023.01.024_bib21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2337\/db10-0867","article-title":"Downregulation of adipose tissue fatty acid trafficking in obesity: a driver for ectopic fat deposition?","volume":"60","author":"McQuaid","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.jhep.2023.01.024_bib22","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2337\/db08-0043","article-title":"Metabolic flexibility in response to glucose is not impaired in people with type 2 diabetes after controlling for glucose disposal rate","volume":"57","author":"Galgani","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.jhep.2023.01.024_bib23","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1042\/CS20170261","article-title":"Metabolic disturbances of non-alcoholic fatty liver resemble the alterations typical for type 2 diabetes","volume":"131","author":"Brouwers","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jhep.2023.01.024_bib24","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s00125-005-1682-x","article-title":"Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms","volume":"48","author":"Bugianesi","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.jhep.2023.01.024_bib25","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of insulin action and insulin resistance","volume":"98","author":"Petersen","year":"2018","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jhep.2023.01.024_bib26","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/0026-0495(92)90269-G","article-title":"Adipose tissue metabolism in obesity: lipase action in\u00a0vivo before and after a mixed meal","volume":"41","author":"Coppack","year":"1992","journal-title":"Metabolism"},{"key":"10.1016\/j.jhep.2023.01.024_bib27","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/j.celrep.2018.04.055","article-title":"Loss of ABHD15 impairs the anti-lipolytic action of insulin by altering PDE3B stability and contributes to insulin resistance","volume":"23","author":"Xia","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.jhep.2023.01.024_bib28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.molmet.2019.05.002","article-title":"ABHD15 regulates adipose tissue lipolysis and hepatic lipid accumulation","volume":"25","author":"St\u00f6ckli","year":"2019","journal-title":"Mol Metab"},{"key":"10.1016\/j.jhep.2023.01.024_bib29","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.bbrc.2006.02.091","article-title":"The 47kDa Akt substrate associates with phosphodiesterase 3B and regulates its level in adipocytes","volume":"342","author":"Chavez","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhep.2023.01.024_bib30","article-title":"Pharmacological inhibition of adipose triglyceride lipase corrects high-fat diet-induced insulin resistance and hepatosteatosis in mice","volume":"8","author":"Schweiger","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2023.01.024_bib31","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1210\/jcem.84.9.6103","article-title":"A\u00a0gene for congenital generalized lipodystrophy maps to human chromosome 9q34","volume":"84","author":"Garg","year":"1999","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jhep.2023.01.024_bib32","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1315496","article-title":"Null mutation in hormone-sensitive lipase gene and risk of type 2 diabetes","volume":"370","author":"Albert","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.01.024_bib33","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.2337\/db16-0213","article-title":"Lipodystrophy due to adipose tissue-specific insulin receptor knockout results in progressive NAFLD","volume":"65","author":"Softic","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.jhep.2023.01.024_bib34","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.molmet.2016.04.001","article-title":"Raptor\/mTORC1 loss in adipocytes causes progressive lipodystrophy and fatty liver disease","volume":"5","author":"Lee","year":"2016","journal-title":"Mol Metab"},{"key":"10.1016\/j.jhep.2023.01.024_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1007110","article-title":"Adipose tissue deficiency of hormone-sensitive lipase causes fatty liver in mice","volume":"13","author":"Xia","year":"2017","journal-title":"Plos Genet"},{"key":"10.1016\/j.jhep.2023.01.024_bib36","first-page":"E1063","article-title":"Regulation of free fatty acid metabolism by insulin in humans: role of lipolysis and reesterification","volume":"263","author":"Campbell","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jhep.2023.01.024_bib37","first-page":"E308","article-title":"Regulation of fatty acid movement in human adipose tissue in the postabsorptive-to-postprandial transition","volume":"266","author":"Frayn","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jhep.2023.01.024_bib38","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.01.024_bib39","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1172\/JCI135431","article-title":"Free fatty acid processing diverges in human pathologic insulin resistance conditions","volume":"130","author":"Sekizkardes","year":"2020","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.01.024_bib40","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jhep.2021.11.009","article-title":"A\u00a0new perspective on NAFLD: focusing on lipid droplets","volume":"76","author":"Scorletti","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.024_bib41","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPAR\u03b1 is crucial for whole-body fatty acid homeostasis and is protective against NAFLD","volume":"65","author":"Montagner","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2023.01.024_bib42","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/liv.14309","article-title":"Dietary fatty acid oxidation is decreased in non-alcoholic fatty liver disease: a palmitate breath test study","volume":"40","author":"Naguib","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2023.01.024_bib43","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/hep.32324","article-title":"Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD","volume":"76","author":"Moore","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.024_bib44","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/MEG.0b013e328345c8c7","article-title":"Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis","volume":"23","author":"Dasarathy","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.01.024_bib45","doi-asserted-by":"crossref","first-page":"15430","DOI":"10.1073\/pnas.0904944106","article-title":"Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity","volume":"106","author":"Fabbrini","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2023.01.024_bib46","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jhep.2021.02.027","article-title":"Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: a randomized controlled trial","volume":"75","author":"Geidl-Flueck","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.024_bib47","doi-asserted-by":"crossref","first-page":"9116","DOI":"10.1073\/pnas.161284298","article-title":"A\u00a0glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver","volume":"98","author":"Yamashita","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2023.01.024_bib48","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.2337\/dc18-0071","article-title":"Saturated fat is more metabolically harmful for the human liver than unsaturated fat or simple sugars","volume":"41","author":"Luukkonen","year":"2018","journal-title":"Diabetes care"},{"key":"10.1016\/j.jhep.2023.01.024_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101210","article-title":"Suppression of insulin-induced gene 1 (INSIG1) function promotes hepatic lipid remodelling and restrains NASH progression","volume":"48","author":"Azzu","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.jhep.2023.01.024_bib50","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1194\/jlr.M052308","article-title":"A\u00a0high-fat diet suppresses de novo lipogenesis and desaturation but not elongation and triglyceride synthesis in mice","volume":"55","author":"Duarte","year":"2014","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2023.01.024_bib51","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.tips.2017.04.004","article-title":"Roles of diacylglycerols and ceramides in hepatic insulin resistance","volume":"38","author":"Petersen","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jhep.2023.01.024_bib52","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.024_bib53","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1371\/journal.pgen.0030064","article-title":"PPAR gamma 2 prevents lipotoxicity by controlling adipose\u00a0tissue\u00a0expandability and peripheral lipid metabolism","volume":"3","author":"Medina-Gomez","year":"2007","journal-title":"Plos Genet"},{"key":"10.1016\/j.jhep.2023.01.024_bib54","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.celrep.2018.07.063","article-title":"Peroxisome proliferator-activated receptor \u03b32 controls the rate of adipose tissue lipid storage and determines metabolic flexibility","volume":"24","author":"Virtue","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.jhep.2023.01.024_bib55","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1097-2765(05)00010-9","article-title":"Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob\/ob mice","volume":"6","author":"Shimomura","year":"2000","journal-title":"Mol Cell"},{"key":"10.1016\/j.jhep.2023.01.024_bib56","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.bbalip.2009.12.006","article-title":"Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome--an allostatic perspective","volume":"1801","author":"Virtue","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jhep.2023.01.024_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9070762","article-title":"Role of leptin in non-alcoholic fatty liver disease","volume":"9","author":"Jim\u00e9nez-Cortegana","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jhep.2023.01.024_bib58","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ajpath.2021.11.008","article-title":"Leptin enhances hepatic fibrosis and inflammation in a mouse model of cholestasis","volume":"192","author":"Petrescu","year":"2022","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2023.01.024_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249368","article-title":"Unraveling the role of leptin in liver function and its relationship with liver diseases","volume":"21","author":"Mart\u00ednez-U\u00f1a","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2023.01.024_bib60","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1053\/jhep.2002.32029","article-title":"Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob\/ob mice","volume":"35","author":"Saxena","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.024_bib61","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0168-8278(02)00414-2","article-title":"Influence of leptin in the development of hepatic fibrosis produced in mice by Schistosoma mansoni infection and by chronic carbon tetrachloride administration","volume":"38","author":"Potter","year":"2003","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.024_bib62","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1053\/gast.2002.32995","article-title":"Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat","volume":"122","author":"Ikejima","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.01.024_bib63","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.gastro.2009.04.011","article-title":"Kupffer cells mediate leptin-induced liver fibrosis","volume":"137","author":"Wang","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.01.024_bib64","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ygcen.2017.02.012","article-title":"Intramuscular injection of exogenous leptin induces adiposity, glucose intolerance and fatty liver by repressing the JAK2-STAT3\/PI3K pathway in a rat model","volume":"252","author":"Wu","year":"2017","journal-title":"Gen Comp Endocrinol"},{"key":"10.1016\/j.jhep.2023.01.024_bib65","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.cmet.2019.08.005","article-title":"Partial leptin reduction as an insulin sensitization and weight loss strategy","volume":"30","author":"Zhao","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2023.01.024_bib66","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1530\/JOE-16-0142","article-title":"Metformin increases hepatic leptin receptor and decreases steatosis in mice","volume":"230","author":"Tang","year":"2016","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.jhep.2023.01.024_bib67","article-title":"Modified SJH alleviates FFAs-induced hepatic steatosis through leptin signaling pathways","volume":"7","author":"Lim","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2023.01.024_bib68","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.2337\/db10-0074","article-title":"Disruption of hepatic leptin signaling protects mice from age- and diet-related glucose intolerance","volume":"59","author":"Huynh","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.jhep.2023.01.024_bib69","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137180","article-title":"Leptin decreases de novo lipogenesis in patients with lipodystrophy","volume":"5","author":"Baykal","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jhep.2023.01.024_bib70","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1038\/s41467-019-10684-1","article-title":"Brain leptin reduces liver lipids by increasing hepatic triglyceride secretion and lowering lipogenesis","volume":"10","author":"Hackl","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2023.01.024_bib71","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1172\/JCI200419511","article-title":"Site and mechanism of leptin action in a rodent form of congenital lipodystrophy","volume":"113","author":"Asilmaz","year":"2004","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.01.024_bib72","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/MCG.0b013e31819e9048","article-title":"Low serum adiponectin levels are predictive of advanced hepatic fibrosis in patients with NAFLD","volume":"43","author":"Savvidou","year":"2009","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2023.01.024_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22709","article-title":"Low serum adiponectin is a predictor of progressing to nonalcoholic fatty liver disease","volume":"33","author":"Zhang","year":"2019","journal-title":"J\u00a0Clin Lab Anal"},{"key":"10.1016\/j.jhep.2023.01.024_bib74","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nm1557","article-title":"Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions","volume":"13","author":"Yamauchi","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2023.01.024_bib75","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bbrc.2009.02.131","article-title":"Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1\/LKB1\/AMPK dependent pathway","volume":"382","author":"Awazawa","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhep.2023.01.024_bib76","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nm.2277","article-title":"Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin","volume":"17","author":"Holland","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2023.01.024_bib77","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/hep.21995","article-title":"Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells","volume":"47","author":"Caligiuri","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.024_bib78","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/jcb.22634","article-title":"Adiponectin\u00a0activation of AMPK disrupts leptin-mediated hepatic fibrosis via\u00a0suppressors of cytokine signaling (SOCS-3)","volume":"110","author":"Handy","year":"2010","journal-title":"J\u00a0Cell Biochem"},{"key":"10.1016\/j.jhep.2023.01.024_bib79","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1053\/j.gastro.2003.08.029","article-title":"Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin","volume":"125","author":"Kamada","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.01.024_bib80","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2337\/db20-1073","article-title":"Adiponectin alleviates diet-induced inflammation in the liver by suppressing MCP-1 expression and macrophage infiltration","volume":"70","author":"Ryu","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.jhep.2023.01.024_bib81","doi-asserted-by":"crossref","first-page":"708","DOI":"10.4254\/wjh.v10.i10.708","article-title":"Adiponectin as a novel biomarker for liver fibrosis","volume":"10","author":"Udomsinprasert","year":"2018","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhep.2023.01.024_bib82","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrm.2016.96","article-title":"Control of brown and beige fat development","volume":"17","author":"Wang","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jhep.2023.01.024_bib83","article-title":"Lower brown adipose tissue activity is associated with non-alcoholic fatty liver disease but not changes in the gut microbiota","volume":"2","author":"Ahmed","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jhep.2023.01.024_bib84","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41591-020-1126-7","article-title":"Brown adipose tissue is associated with cardiometabolic health","volume":"27","author":"Becher","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2023.01.024_bib85","doi-asserted-by":"crossref","first-page":"E945","DOI":"10.1152\/ajpendo.00473.2013","article-title":"Brown and white adipose tissues: intrinsic differences in gene expression and response to cold exposure in mice","volume":"306","author":"Rosell","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jhep.2023.01.024_bib86","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/nm.3713","article-title":"The brown fat-enriched secreted factor Nrg4 preserves metabolic homeostasis through attenuation of hepatic lipogenesis","volume":"20","author":"Wang","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2023.01.024_bib87","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.molmet.2017.03.016","article-title":"Nrg4 promotes fuel oxidation and a healthy adipokine profile to ameliorate diet-induced metabolic disorders","volume":"6","author":"Chen","year":"2017","journal-title":"Mol Metab"},{"key":"10.1016\/j.jhep.2023.01.024_bib88","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1172\/JCI96324","article-title":"Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression","volume":"127","author":"Guo","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.01.024_bib89","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.cmet.2022.07.010","article-title":"Neuregulin 4 suppresses NASH-HCC development by restraining tumor-prone liver microenvironment","volume":"34","author":"Zhang","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2023.01.024_bib90","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.bbrc.2018.06.043","article-title":"Neuregulin-4 is an angiogenic factor that is critically involved in the maintenance of adipose tissue vasculature","volume":"503","author":"Nugroho","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhep.2023.01.024_bib91","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1038\/s41467-018-07453-x","article-title":"Adipocyte-secreted BMP8b mediates adrenergic-induced remodeling of the neuro-vascular network in adipose tissue","volume":"9","author":"Pellegrinelli","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2023.01.024_bib92","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.14555","article-title":"Serum neuregulin 4 (NRG-4) level and non-alcoholic fatty\u00a0liver\u00a0disease (NAFLD): a case-control study","volume":"75","author":"Tutunchi","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jhep.2023.01.024_bib93","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.metabol.2015.08.013","article-title":"A\u00a0case-control study: association between serum neuregulin 4 level and non-alcoholic fatty liver disease","volume":"64","author":"Dai","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.jhep.2023.01.024_bib94","article-title":"Is there a role for neuregulin 4 in human nonalcoholic fatty liver disease?","volume":"16","author":"De Munck Tji","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2023.01.024_bib95","doi-asserted-by":"crossref","DOI":"10.1172\/JCI144801","article-title":"Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2","volume":"131","author":"Liu","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.01.024_bib96","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1084\/jem.20081880","article-title":"Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions","volume":"206","author":"Serhan","year":"2009","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jhep.2023.01.024_bib97","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s42255-022-00590-0","article-title":"Brown adipose tissue-derived MaR2 contributes to cold-induced resolution of inflammation","volume":"4","author":"Sugimoto","year":"2022","journal-title":"Nat Metab"},{"key":"10.1016\/j.jhep.2023.01.024_bib98","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/gutjnl-2019-319227","article-title":"TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms","volume":"70","author":"Esparza-Baquer","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2023.01.024_bib99","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.cell.2019.05.054","article-title":"Lipid-associated macrophages control metabolic homeostasis in a trem2-dependent manner","volume":"178","author":"Jaitin","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2023.01.024_bib100","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jhep.2022.05.044","article-title":"TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation","volume":"77","author":"Labiano","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.024_bib101","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1515\/bchm2.1977.358.1.639","article-title":"[Isolation and characterization of an unknown, leucine-rich 3.1-S-alpha2-glycoprotein from human serum (author's transl)]","volume":"358","author":"Haupt","year":"1977","journal-title":"Hoppe Seylers Z Physiol Chem"},{"key":"10.1016\/j.jhep.2023.01.024_bib102","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148545","article-title":"LRG1 is an adipokine that mediates obesity-induced hepatosteatosis and insulin resistance","volume":"131","author":"He","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.01.024_bib103","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1172\/JCI129193","article-title":"Interorgan communication by exosomes, adipose tissue, and adiponectin in metabolic syndrome","volume":"129","author":"Kita","year":"2019","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.01.024_bib104","doi-asserted-by":"crossref","DOI":"10.3390\/biom10111494","article-title":"Extracellular vesicles in the development of the non-alcoholic fatty liver disease: an update","volume":"10","author":"Dorairaj","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.jhep.2023.01.024_bib105","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.cell.2017.08.035","article-title":"Adipose tissue macrophage-derived exosomal miRNAs can modulate in\u00a0vivo and in\u00a0vitro insulin sensitivity","volume":"171","author":"Ying","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2023.01.024_bib106","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1053\/j.gastro.2021.05.008","article-title":"Associations among adipose tissue immunology, inflammation, exosomes and insulin sensitivity in people with obesity and nonalcoholic fatty liver disease","volume":"161","author":"Fuchs","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.01.024_bib107","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature21365","article-title":"Adipose-derived circulating miRNAs regulate gene expression in other tissues","volume":"542","author":"Thomou","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2023.01.024_bib108","doi-asserted-by":"crossref","first-page":"483","DOI":"10.33549\/physiolres.932714","article-title":"Changes in FGF21 serum concentrations and liver mRNA expression in an experimental model of complete lipodystrophy and insulin-resistant diabetes","volume":"63","author":"Spolcov\u00e1","year":"2014","journal-title":"Physiol Res"},{"key":"10.1016\/j.jhep.2023.01.024_bib109","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.cyto.2016.04.015","article-title":"Serum concentrations of fibroblast growth factor 21 are elevated in patients with congenital or acquired lipodystrophy","volume":"83","author":"Miehle","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.jhep.2023.01.024_bib110","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/hep.29343","article-title":"Adipose-derived exosomal MicroRNAs orchestrate gene regulation in the liver: is this the missing link in nonalcoholic fatty liver disease?","volume":"66","author":"Korf","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.024_bib111","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrgastro.2017.71","article-title":"Extracellular vesicles in liver disease and potential as biomarkers and therapeutic targets","volume":"14","author":"Szabo","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.01.024_bib112","doi-asserted-by":"crossref","DOI":"10.1210\/endrev\/bnaa004","article-title":"Metabolically healthy obesity","volume":"41","author":"Bl\u00fcher","year":"2020","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jhep.2023.01.024_bib113","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1053\/j.gastro.2019.12.054","article-title":"Adipose tissue-liver cross talk in the control of whole-body metabolism: implications in nonalcoholic fatty liver disease","volume":"158","author":"Azzu","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.01.024_bib114","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1055\/s-0039-1687851","article-title":"Macrophages as key players during adipose tissue-liver crosstalk in nonalcoholic fatty liver disease","volume":"39","author":"Korf","year":"2019","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2023.01.024_bib115","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2015.05.044","article-title":"Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease","volume":"149","author":"du Plessis","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.01.024_bib116","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.cell.2014.05.012","article-title":"Increased adipocyte O2 consumption triggers HIF-1\u03b1, causing inflammation and insulin resistance in obesity","volume":"157","author":"Lee","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2023.01.024_bib117","doi-asserted-by":"crossref","first-page":"6688","DOI":"10.1172\/JCI141828","article-title":"Decreased adipose tissue oxygenation associates with insulin resistance in individuals with obesity","volume":"130","author":"Cifarelli","year":"2020","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.01.024_bib118","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1172\/JCI45887","article-title":"Adipose tissue remodeling and obesity","volume":"121","author":"Sun","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.01.024_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101010","article-title":"Suppressing adipocyte inflammation promotes insulin resistance in mice","volume":"39","author":"Zhu","year":"2020","journal-title":"Mol Metab"},{"key":"10.1016\/j.jhep.2023.01.024_bib120","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1038\/ncomms5982","article-title":"Macrophage-inducible C-type lectin underlies obesity-induced adipose tissue fibrosis","volume":"5","author":"Tanaka","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2023.01.024_bib121","doi-asserted-by":"crossref","first-page":"C375","DOI":"10.1152\/ajpcell.00379.2020","article-title":"Adipose tissue inflammation and metabolic\u00a0dysfunction in obesity","volume":"320","author":"Kawai","year":"2021","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jhep.2023.01.024_bib122","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","article-title":"Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits","volume":"77","author":"Peiseler","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.01.024_bib123","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/db15-0941","article-title":"Mesenteric fat lipolysis mediates obesity-associated hepatic steatosis and insulin resistance","volume":"65","author":"Wueest","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.jhep.2023.01.024_bib124","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/hep.27016","article-title":"Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer","volume":"60","author":"Aleksandrova","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.024_bib125","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1007\/s00125-010-1865-y","article-title":"Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance","volume":"53","author":"Matthews","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.jhep.2023.01.024_bib126","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/hep.1840190229","article-title":"Endotoxin-induced cytokine gene expression and excretion in the liver","volume":"19","author":"Luster","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.024_bib127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.orcp.2016.03.009","article-title":"Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity","volume":"12","author":"Jorge","year":"2018","journal-title":"Obes Res Clin Pract"},{"key":"10.1016\/j.jhep.2023.01.024_bib128","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature10809","article-title":"Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity","volume":"482","author":"Henao-Mejia","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2023.01.024_bib129","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/gut.2005.071118","article-title":"Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice","volume":"55","author":"Tomita","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2023.01.024_bib130","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.3748\/wjg.v26.i33.4933","article-title":"Tumor necrosis factor alpha receptor 1 deficiency in hepatocytes does not protect from non-alcoholic steatohepatitis, but attenuates insulin resistance in mice","volume":"26","author":"Bluemel","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2023.01.024_bib131","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1007\/s00125-012-2710-2","article-title":"Monocyte chemoattractant protein-1 (MCP-1) deficiency enhances alternatively activated M2 macrophages and ameliorates insulin resistance and fatty liver in lipoatrophic diabetic A-ZIP transgenic mice","volume":"55","author":"Nio","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.jhep.2023.01.024_bib132","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.yexmp.2011.08.001","article-title":"Elevated systemic monocyte chemoattractrant protein-1 in hepatic steatosis without significant hepatic inflammation","volume":"91","author":"Kirovski","year":"2011","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.jhep.2023.01.024_bib133","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jhep.2006.02.011","article-title":"Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2","volume":"44","author":"Haukeland","year":"2006","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.024_bib134","doi-asserted-by":"crossref","first-page":"8656","DOI":"10.1074\/jbc.RA117.001653","article-title":"Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis","volume":"293","author":"Zou","year":"2018","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2023.01.024_bib135","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1038\/labinvest.2010.143","article-title":"Monocyte chemoattractant protein-1 deficiency does not affect steatosis or inflammation in livers of mice fed a methionine-choline-deficient diet","volume":"90","author":"Kassel","year":"2010","journal-title":"Lab Invest"},{"key":"10.1016\/j.jhep.2023.01.024_bib136","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s42255-021-00354-2","article-title":"Metabolic messengers: FGF21","volume":"3","author":"Flippo","year":"2021","journal-title":"Nat Metab"},{"key":"10.1016\/j.jhep.2023.01.024_bib137","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","article-title":"Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21","volume":"5","author":"Inagaki","year":"2007","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2023.01.024_bib138","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1210\/en.2011-0281","article-title":"Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in\u00a0vivo","volume":"152","author":"Fisher","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.jhep.2023.01.024_bib139","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.omtm.2020.12.011","article-title":"Visceral adipose tissue-directed FGF21 gene therapy improves metabolic and immune health in BTBR mice","volume":"20","author":"Queen","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jhep.2023.01.024_bib140","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.01.024_bib141","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1210\/en.2009-0119","article-title":"Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver","volume":"150","author":"Hotta","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.jhep.2023.01.024_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109331","article-title":"FGF21 promotes thermogenic gene expression as an autocrine factor in adipocytes","volume":"35","author":"Abu-Odeh","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.jhep.2023.01.024_bib143","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1101\/gad.177857.111","article-title":"FGF21 regulates PGC-1\u03b1 and browning of white adipose tissues in adaptive thermogenesis","volume":"26","author":"Fisher","year":"2012","journal-title":"Genes Dev"},{"key":"10.1016\/j.jhep.2023.01.024_bib144","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.febslet.2008.04.038","article-title":"FGF21 attenuates lipolysis in human adipocytes - a possible link to improved insulin sensitivity","volume":"582","author":"Arner","year":"2008","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jhep.2023.01.024_bib145","article-title":"AKR-001, an fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism in type 2 diabetes patients","volume":"1","author":"Kaufman","year":"2020","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jhep.2023.01.024_bib146","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2023.01.024_bib147","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/oby.22344","article-title":"Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study","volume":"27","author":"Charles","year":"2019","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jhep.2023.01.024_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106335","article-title":"The FALCON program: two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis","volume":"104","author":"Abdelmalek","year":"2021","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jhep.2023.01.024_bib149","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/00365521.2017.1392596","article-title":"PRO-C3: a new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C","volume":"53","author":"Hansen","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2023.01.024_bib150","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/978-1-59745-447-6_7","article-title":"YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation","volume":"511","author":"Roslind","year":"2009","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jhep.2023.01.024_bib151","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1210\/me.2010-0142","article-title":"Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse","volume":"24","author":"Fon Tacer","year":"2010","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.jhep.2023.01.024_bib152","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.cmet.2017.09.005","article-title":"FGF19, FGF21, and an FGFR1\/\u03b2-klotho-activating antibody act on the nervous system to regulate body weight and glycemia","volume":"26","author":"Lan","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2023.01.024_bib153","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic","volume":"16","author":"Geng","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jhep.2023.01.024_bib154","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2023.01.024_bib155","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2023.01.024_bib156","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jhep.2015.11.031","article-title":"Time for Glucagon like peptide-1 receptor\u00a0agonists treatment for patients with NAFLD?","volume":"64","author":"Gastaldelli","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.024_bib157","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in\u00a0vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.024_bib158","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1478-3231.2011.02462.x","article-title":"Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis","volume":"31","author":"Svegliati-Baroni","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2023.01.024_bib159","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0014-5793(94)01430-9","article-title":"Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences","volume":"358","author":"Wei","year":"1995","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jhep.2023.01.024_bib160","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2967\/jnumed.106.038679","article-title":"GLP-1 receptor expression in human tumors and human normal tissues: potential for in\u00a0vivo targeting","volume":"48","author":"K\u00f6rner","year":"2007","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.jhep.2023.01.024_bib161","doi-asserted-by":"crossref","first-page":"E701","DOI":"10.1152\/ajpendo.00024.2003","article-title":"Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect","volume":"285","author":"Prigeon","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jhep.2023.01.024_bib162","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s00125-012-2738-3","article-title":"Direct effect of GLP-1 infusion on endogenous glucose production in humans","volume":"56","author":"Seghieri","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.jhep.2023.01.024_bib163","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.01.024_bib164","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1007\/s00125-012-2592-3","article-title":"Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes","volume":"55","author":"Lee","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.jhep.2023.01.024_bib165","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.3389\/fphar.2018.01168","article-title":"GLP-1 improves adipocyte insulin sensitivity following induction of endoplasmic reticulum stress","volume":"9","author":"Jiang","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jhep.2023.01.024_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103382","article-title":"Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice","volume":"24","author":"Zhang","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.jhep.2023.01.024_bib167","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2213-8587(21)00179-0","article-title":"Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial","volume":"9","author":"Neeland","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jhep.2023.01.024_bib168","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.01.024_bib169","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.cell.2005.11.026","article-title":"The many faces of PPARgamma","volume":"123","author":"Lehrke","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2023.01.024_bib170","doi-asserted-by":"crossref","first-page":"E225","DOI":"10.1152\/ajpendo.90960.2008","article-title":"Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients","volume":"297","author":"Gastaldelli","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jhep.2023.01.024_bib171","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/hep.23116","article-title":"Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis","volume":"50","author":"Gastaldelli","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.024_bib172","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1111\/liv.15005","article-title":"PPAR-\u03b3-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH","volume":"41","author":"Gastaldelli","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2023.01.024_bib173","doi-asserted-by":"crossref","first-page":"22504","DOI":"10.1073\/pnas.0912487106","article-title":"PPARgamma activation in adipocytes is sufficient for systemic insulin sensitization","volume":"106","author":"Sugii","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2023.01.024_bib174","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0168-8278(01)00066-6","article-title":"Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones","volume":"35","author":"Bedoucha","year":"2001","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.024_bib175","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1172\/JCI200317223","article-title":"Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes","volume":"111","author":"Matsusue","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.01.024_bib176","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/JOE-16-0447","article-title":"Hepatocyte-specific, PPAR\u03b3-regulated mechanisms to promote steatosis in adult mice","volume":"232","author":"Wolf Greenstein","year":"2017","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.jhep.2023.01.024_bib177","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.jcmgh.2021.01.003","article-title":"Hepatocyte-specific loss of PPAR\u03b3 protects mice from NASH and increases the therapeutic effects of rosiglitazone in the liver","volume":"11","author":"Lee","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.01.024_bib178","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cellimm.2009.04.003","article-title":"PPAR gamma is highly expressed in F4\/80(hi) adipose tissue macrophages and dampens adipose-tissue inflammation","volume":"258","author":"Bassaganya-Riera","year":"2009","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jhep.2023.01.024_bib179","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jhep.2013.06.023","article-title":"Cell-specific PPAR\u03b3 deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells","volume":"59","author":"Mor\u00e1n-Salvador","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.024_bib180","article-title":"Effect of modulation of PPAR-\u03b3 activity on Kupffer cells M1\/M2 polarization in the development of non-alcoholic fatty liver disease","volume":"7","author":"Luo","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2023.01.024_bib181","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s13105-020-00777-7","article-title":"Regulation of peroxisome proliferator-activated receptor-gamma activity affects the hepatic stellate cell activation and the progression of NASH via TGF-\u03b21\/Smad signaling pathway","volume":"77","author":"Ni","year":"2021","journal-title":"J\u00a0Physiol Biochem"},{"key":"10.1016\/j.jhep.2023.01.024_bib182","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/liv.14385","article-title":"Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes","volume":"40","author":"Yen","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2023.01.024_bib183","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2017.12.001","article-title":"Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes","volume":"16","author":"Bril","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.01.024_bib184","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2023.01.024_bib185","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1463-1326.2011.01429.x","article-title":"Metabolic effects of muraglitazar in type 2 diabetic subjects","volume":"13","author":"Fernandez","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jhep.2023.01.024_bib186","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.cgh.2020.10.051","article-title":"A\u00a0phase 2 double blinded, randomized controlled trial of saroglitazar in patients with nonalcoholic steatohepatitis","volume":"19","author":"Siddiqui","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.01.024_bib187","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A\u00a0randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.01.024_bib188","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jhep.2012.02.027","article-title":"Non-alcoholic fatty liver disease across the spectrum of hypothyroidism","volume":"57","author":"Chung","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.024_bib189","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1210\/jc.2016-1300","article-title":"Thyroid function and the risk of nonalcoholic fatty liver disease: the rotterdam study","volume":"101","author":"Bano","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jhep.2023.01.024_bib190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249614","article-title":"The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"16","author":"D'Ambrosio","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2023.01.024_bib191","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3350\/cmh.2015.21.4.372","article-title":"Impact of hypothyroidism on the development of non-alcoholic fatty liver disease: a 4-year retrospective cohort study","volume":"21","author":"Lee","year":"2015","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2023.01.024_bib192","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000454920","article-title":"Nonalcoholic fatty liver\u00a0disease\u00a0is not associated with thyroid hormone levels and hypothyroidism: a systematic review and meta-analysis","volume":"6","author":"Jaruvongvanich","year":"2017","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.jhep.2023.01.024_bib193","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.tem.2022.08.001","article-title":"NAFLD and thyroid function: pathophysiological and therapeutic considerations","volume":"33","author":"Hatziagelaki","year":"2022","journal-title":"Trends Endocrinology Metabolism: TEM"},{"key":"10.1016\/j.jhep.2023.01.024_bib194","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1172\/JCI6397","article-title":"Divergent roles for thyroid hormone receptor beta isoforms in the endocrine axis and auditory system","volume":"104","author":"Abel","year":"1999","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.01.024_bib195","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1210\/me.2008-0311","article-title":"Distinct dysregulation of lipid metabolism by unliganded thyroid hormone receptor isoforms","volume":"23","author":"Araki","year":"2009","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.jhep.2023.01.024_bib196","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1089\/thy.2020.0651","article-title":"Increased hepatic fat content in patients with resistance to thyroid hormone beta","volume":"31","author":"Chaves","year":"2021","journal-title":"Thyroid"},{"key":"10.1016\/j.jhep.2023.01.024_bib197","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2023.01.024_bib198","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2023.01.024_bib199","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.eprac.2022.03.360","article-title":"Abstract #1184634: effect of resmetirom, a selective thyroid hormone receptor beta agonist, on hepatic hypothyroidism in a 52-week non-cirrhotic NASH phase 3 clinical trial","volume":"28","author":"Lucas","year":"2022","journal-title":"Endocr Pract"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823000776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823000776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:47:22Z","timestamp":1759175242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827823000776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":199,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0168827823000776"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2023.01.024","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2023.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}